Autism Spectrum Disorders Segmentation
Type(Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder (PDD-NOS))
Based on type, the autistic disorder segment is expected to hold the largest share of 42.4% in the autism spectrum disorders market over the assessed period. Having a higher prevalence, this neurodegenerative illness has become a primary concern for healthcare authorities, which is further pushing them to invest more in this category. In this regard, the CDC calculated the occurrence rate of autistic disorder in the U.S. among children to be 1 per 37 in 2024. Additionally, this segment is witnessing greater R&D activities due to its severity and complexity, where the National Institute of Health (NIH) estimated its captivity over net ASD R&D-related expenditure to surpass 60.4% by 2030.
Treatment (Behavioral Therapy (ABA), Speech Therapy, Occupational Therapy, Medication)
In terms of treatment, the behavioral therapy segment is poised to dominate the autism spectrum disorders market with a share of 38.5% by the end of 2037. The clinical and financial benefits of this therapy are a few of the major reasons behind its preferred use in treating ASD-related ailments. Testifying this, the AHRQ published a study on applied behavior analysis (ABA) therapy as a first-line treatment in 2022, demonstrating a 23.4% reduction in expenses on hospital admissions in the U.S. landscape. Based on such validation, the U.S. Medicaid expanded its coverage for this segment to 55.1%. This upstream flow in insurer reimbursement rates is broadening the range and volume of adoption around the globe.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Treatment |
|
|
End user |
|
